February 8, 2022 Word for Word Media

Here is a patient journey to help show you what your treatment may look like if you are diagnosed with ovarian cancer. Click here to download a PDF of the ovarian cancer patient journey.

You can listen to this article below, or by using your favourite podcast player at pod.link/oncologybuddies

References American Cancer Society (ACS). Ovarian Cancer Detailed Guide. American Cancer Society, Inc. February 2016:1-63. Jasen P. From the “silent killer” to the “whispering disease”: ovarian cancer and the uses of metaphor. Med Hist. 2009;53(4):489-512. Armstrong DK, Plaxe SC, Alvarez RD et al. NCCN Clinical Practice Guidelines in Oncology…

October 1, 2021 Word for Word Media

The road to the best breast cancer outcomes is paved with information, multi-disciplinary care and personalised oncology. You can’t change the diagnosis, but you can control how you manage the journey. Sysmex is proud to bring you the first breast cancer patient journey to help you navigate through it. Click here to download a PDF of the breast cancer patient journey.

August 2, 2021 Word for Word Media

Ferring in collaboration with The Prostate Cancer Foundation of South Africa are proud to present the first metastatic prostate cancer patient journey. This is the possible route of your treatment journey for your ease of reference and understanding. Click here to download a PDF of the metastatic prostate cancer patient journey.

References Moul J, et al. Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification. Official reprint from UpToDate. UpToDate. Waltham, MA, 2021. Kirby RS, Patel I. Fast Facts: Prostate Cancer. Eighth edition. Health Press Limited. Jan 2014. Kantoff PW, Taplin M-E, et al. Clinical…

May 25, 2021 Word for Word Media

Oncology Buddies is proud to present the first Advanced NSCLC ALK+ lung cancer patient journey for your ease of reference and understanding of the route your journey may look like. Please note: this patient journey is only for ALK+ lung cancer and not applicable for all lung cancer patients.